There are currently 98 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Salinas Valley Memorial Healthcare System, Salinas, California +8 locations
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612
Recruiting
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut +18 locations
Conditions: Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
Register for Updates
Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
NCT06276491
Recruiting
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.
Gender:
All
Ages:
15 years and above
Trial Updated:
05/21/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan +3 locations
Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Register for Updates
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068
Recruiting
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/21/2024
Locations: Research Site, San Francisco, California +75 locations
Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Michael Birrer, MD, PhD, Little Rock, Arkansas +8 locations
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates
Vaginal Cuff Brachytherapy Fractionation Study
NCT03785288
Recruiting
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: University of Maryland Medical Center (UMMC), Baltimore, Maryland +2 locations
Conditions: Endometrial Cancer
Register for Updates
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT05051722
Recruiting
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Mayo Clinic, Phoenix, Arizona +14 locations
Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Register for Updates
ASk Questions in GYnecologic Oncology (ASQ-GYO)
NCT06339827
Recruiting
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Gestational Trophoblastic Disease
Register for Updates
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT06136884
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Oklahoma Univeristy, Oklahoma City, Oklahoma +3 locations
Conditions: Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer
Register for Updates
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT05761951
Recruiting
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT02628067
Recruiting
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Call for Information (Investigational Site 0008), New Brunswick, New Jersey +22 locations
Conditions: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
Register for Updates
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT06299163
Recruiting
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
Register for Updates